Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million on August 18, 2023. In similar transaction Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million. Qingdao Laoshan District Finance Bureau and Qingdao State-owned Assets Supervision and Administration Commission, approved for Huilong Huaze to acquire 9,720,000 shares in Hangzhou TianMuShan from Yongxin Huarui.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.65 CNY | +1.86% |
|
+3.24% | -34.39% |
1st Jan change | Capi. | |
---|---|---|
-34.39% | 128M | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- 600671 Stock
- News Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
- Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million.